ストックスクリーナーアプリを入手
0.2718
0.15%
-0.0004
Medicus Pharma Ltd (MDCX) 最新ニュース
Medicus (MDCXW) Session: Ends a Quiet Session at $0.33 for the Current Session; Range Check: the Current Price Sits Inside the Supplied Technical Range in the Available RecordStock News - vinanet.vn
Medicus (MDCXW) Shares: Records a Muted Move to $0.33 in the Latest Session; Price Setup: Price Remains Between $0.31 Support and $0.35 Resistance in the Current UpdateCall Spread Alert - vinanet.vn
Medicus Pharma Ltd. Common Stock (NASDAQ: MDCX) Stock Price, News & Analysis - Kalkine
Medicus (MDCX) Quarterly Figures: The EPS Result Is Below Expectation in the Available Record; The Market Price Advances 1.15%Earnings Call Highlights - vinanet.vn
Medicus Pharma on Bloomberg World - Coldwater Daily Reporter
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - dailyrecord.com
Top Medicus Pharma (MDCXW) Competitors 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Market movers: Cisco, Cerebras, Medicus Pharma, Ideal Power... - Proactive financial news
Medicus Pharma advances clinical programs and r... - Pluang
Medicus Pharma advances pipeline during Q2 with key milestones - Yahoo Finance
Medicus Pharma Q2 loss widens to $11.7M, misses EPS estimate - scanx.trade
Medicus Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Corsicana Daily Sun
Medicus Pharma Ltd. Q2 2026: Net loss $(11.62M), EPS $(0.21) — 10-Q Summary - TradingView
Medicus Pharma (MDCX) widens loss as it raises $32M and adds secured notes - Stock Titan
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Medicus Pharma (MDCX) Climbs 8.08% to $0.35 as Buying Interest BuildsHedge Fund Favorites - vinanet.vn
This 1 Stock Has Potential To Change Lives Maneskin (sRqAItrCwb) - Mshale
Price to book forward of Medicus Pharma Ltd. – NASDAQ:MDCX - TradingView
Price to earnings forward of Medicus Pharma Ltd. – NASDAQ:MDCX - TradingView
Medicus Pharma Ltd expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Medicus Pharma Ltd. Revenue Breakdown – BOATS:MDCXW - TradingView
Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev - Investing.com
Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev By Investing.com - Investing.com Nigeria
Medicus Pharma Names Dr. Faisal Mehmud CEO of UK Subsidiary Antev - citybiz
Medicus Pharma Appoints New CEO to Drive Development - Intellectia AI
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - The Manila Times
Medicus Pharma targets Gorlin Syndrome with SkinJectICYMI - Proactive financial news
Small cap wrap: Medicus Pharma, Tiziana Life Sciences, Namibia Critical Metals... - Proactive financial news
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix - Yahoo! Finance Canada
Medicus Pharma receives UAE approval for endometriosis study By Investing.com - Investing.com Nigeria
Medicus Pharma Secures IND Authorization for Teverelix® Study in UAE - Intellectia AI
Medicus Pharma Ltd. (MDCX) Q1 2026 Earnings: Larger-than-Expected Loss Reported, Stock Edges Higher - Vinanet
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – BOATS:MDCX - TradingView
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (NASDAQ:MDCX) - Proactive financial news
Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome - Proactive financial news
Small cap wrap: Nextsource Materials, First Phosphate, Medicus Pharma, Nextech3D.ai… - Proactive financial news
FDA clears Medicus Pharma to start Phase 2b tri... - Pluang
Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome - Yahoo Finance
Medicus Pharma Receives FDA 'Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome - The Manila Times
FDA clears Medicus Pharma to start pivotal SkinJect trial for Gorlin Syndrome skin cancer treatment - Pluang
FDA clears Medicus Pharma Gorlin Syndrome study to proceed - Investing.com
Medicus Pharma Receives FDA “Study May Proceed” Letter for - GlobeNewswire
Medicus Pharma Ltd (MDCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd. Revenue Breakdown – NASDAQ:MDCXW - TradingView
Medicus Pharma Ltd (MDCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings - Moomoo
MDCX|Medicus Pharma Ltd|Price:0.370|Chg%:-0.014 - TradingKey
TradingKey - TradingKey
Medicus Pharma Ltd (MDCX) Institutional Confidence - TradingKey
Medicus Pharma Ltd. Revenue Breakdown – NASDAQ:MDCX - TradingView
MDCX|Medicus Pharma Ltd|Price:0.303|Chg%:-0.015 - TradingKey
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review - MyChesCo
Medicus Pharma Ltd. (MDCX) Declines 7.39% as Stock Approaches Key Support at $0.36WMA Signal - dars.gov.et
Medicus Pharma CEO details Teverelix progress – ICYMI - Proactive financial news
Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds - MyChesCo
1.01%
大文字化:
|
ボリューム (24 時間):